Zimmermann Carolyne 4
4 · 4D Molecular Therapeutics Inc. · Filed Jun 9, 2021
Insider Transaction Report
Form 4
Zimmermann Carolyne
Chief Business Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-06-07+60,000→ 60,000 totalExercise: $26.83Exp: 2031-06-06→ Common Stock (60,000 underlying)
Footnotes (1)
- [F1]The stock option will vest with respect to 25% of the total number of the underlying shares on June 7, 2022, and the remaining shares will vest in equal monthly installments over the following three-year period, such that the stock option will be fully vested on June 7, 2025, subject to the Reporting Person continuing to be a service provider to Issuer through each vesting date.